Ozempic vs Wegovy vs Mounjaro vs Zepbound
The four brand names dominating GLP-1 peptide therapy represent just two actual molecules — semaglutide (Ozempic and Wegovy) from Novo Nordisk, and tirzepatide (Mounjaro and Zepbound) from Eli Lilly. The split between brand names reflects FDA indications: one pair is labeled for type 2 diabetes, the other for chronic weight management. For patients and investors trying to make sense of the market, understanding which brand corresponds to which indication — and what that means for insurance coverage, pricing, and availability — is essential.
Last updated: April 8, 2026
Semaglutide (Ozempic + Wegovy)
Two brand names, one molecule. Ozempic is semaglutide indicated for type 2 diabetes (2017). Wegovy is the same peptide at a higher dose, indicated for chronic weight management (2021). Both are weekly subcutaneous injections manufactured by Novo Nordisk.
Tirzepatide (Mounjaro + Zepbound)
Two brand names, one molecule. Mounjaro is tirzepatide indicated for type 2 diabetes (2022). Zepbound is the same peptide indicated for chronic weight management (2023). Both are weekly subcutaneous injections manufactured by Eli Lilly.
Key Specifications
| Feature | Semaglutide (Ozempic + Wegovy) | Tirzepatide (Mounjaro + Zepbound) |
|---|---|---|
| Molecule | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Ozempic indication | Type 2 Diabetes | — |
| Wegovy indication | Chronic weight management + CV risk reduction | — |
| Dosing | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Max weight loss | ~15% (Wegovy STEP trials) | ~20.9% (SURMOUNT-1) |
| Manufacturer | Novo Nordisk (NVO) | Eli Lilly (LLY) |
| US list price (Wegovy) | ~$1,350/month | — |
| US list price (Ozempic) | ~$950/month | — |
| FDA approval (Ozempic) | 2017 | — |
| FDA approval (Wegovy) | 2021 | — |
| Mounjaro indication | — | Type 2 Diabetes |
| Zepbound indication | — | Chronic weight management + OSA |
| US list price (Zepbound) | — | ~$1,060/month |
| US list price (Mounjaro) | — | ~$1,070/month |
| FDA approval (Mounjaro) | — | 2022 |
| FDA approval (Zepbound) | — | 2023 |
Semaglutide (Ozempic + Wegovy)
Advantages
- Ozempic is covered by most insurance for diabetes
- Wegovy FDA-approved for cardiovascular risk reduction in obese adults without diabetes (2024)
- Rybelsus offers an oral alternative (same molecule)
- Strongest real-world safety data (launched 2017)
- SELECT trial showed 20% MACE reduction
Limitations
- Wegovy supply has been constrained since launch
- Wegovy often not covered by insurance for weight loss only
- US list price ~$1,350/month (Wegovy)
- Less weight loss than tirzepatide head-to-head
Tirzepatide (Mounjaro + Zepbound)
Advantages
- Greater weight loss head-to-head — up to ~22% at highest dose
- Dual GLP-1 + GIP mechanism
- Zepbound FDA-approved for obstructive sleep apnea (2024)
- Lilly has invested heavily in manufacturing capacity — better availability
- Slightly lower US list price than Wegovy
Limitations
- Shorter clinical track record (launched 2022)
- No oral formulation yet
- Cardiovascular outcomes trial (SURPASS-CVOT) not yet fully mature
- Insurance coverage for Zepbound still limited outside diabetes
The Verdict
The simplest mental model: Ozempic and Mounjaro are for diabetes; Wegovy and Zepbound are the same molecules branded for weight loss. Choose semaglutide (Ozempic/Wegovy) if you want the stronger cardiovascular evidence base, the oral option, or if your insurance covers it for your indication. Choose tirzepatide (Mounjaro/Zepbound) if weight loss is the primary goal and your insurance plays along. In practice, insurance coverage and pharmacy availability often dictate the choice more than clinical nuances. Both represent the same underlying peptide therapeutic revolution — the real story is that humanity now has pharmacological tools that reliably reduce body weight by 15–20% with cardiovascular benefits, something unimaginable just a decade ago.